Morgan Stanley analyst Toni Kaplan lowered the firm’s price target on Clarivate (CLVT) to $5 from $8 and keeps an Equal Weight rating on the shares. Organic growth missed in every segment as headwinds mount across the business, leading to the removal of guidance, the analyst tells investors in a research note. The firm added that Clarivate remains a “show me” story, and that it will look for evidence of the new CEO’s plan in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CLVT:
- Clarivate trading resumes
- Clarivate trading halted, volatility trading pause
- Clarivate downgraded to Market Perform from Outperform at William Blair
- Clarivate Faces Revenue Decline Amid Strategic Shift
- Clarivate reports Q3 adjusted EPS 19c, consensus 19c
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
